retatrutide phase 3 trials Shows 28.3% Weight Loss in Obesity Trial New GLP-3 drug significantly slashes

Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Trial 8 (NCT02692716) was a multi-center, multi-national, placebo-controlled, double-blind trial

The fluids previously obtained from food must come from deliberate hydration

These medications mimic the natural GLP-1 hormone that helps regulate appetite, blood sugar levels, and digestion

If your sulfur burps started before your GLP-1 medication and worsened after starting, or if they are accompanied by stomach pain, loss of appetite beyond what the medication explains, or dark stools, H

With stronger weight loss results and added cardiovascular protection, the approval itself has the potential to transform how obesity is treated worldwide